Loading patent…
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Cayla
InventorsLOUIS BUSCAIL, GERARD TIRABY, FABIENNE VERNEJOUL, CHRISTIANE SUSINI, DANIEL DROCOURT
Estimating the term…
The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.
A method for treating cancer comprising the simultaneous, separate, or sequential administration of:
A pharmaceutical composition comprising:
A plasmid vector comprising the sequence SEQ ID NO:11, and comprising nucleic acid sequences coding for the Homo sapiens somatostatin 2 receptor protein and for a polypeptide comprising the two proteins Homo sapiens deoxycytidine kinase protein (dck) and Homo sapiens uridine monophosphate kinase protein (umk) linked by the cleavable Foot-and-Mouth-Disease virus (FMDV) 2A peptide.
Dependencies are inferred from the claim text.